PE20161558A1 - Nuevo compuesto - Google Patents
Nuevo compuestoInfo
- Publication number
- PE20161558A1 PE20161558A1 PE2016001934A PE2016001934A PE20161558A1 PE 20161558 A1 PE20161558 A1 PE 20161558A1 PE 2016001934 A PE2016001934 A PE 2016001934A PE 2016001934 A PE2016001934 A PE 2016001934A PE 20161558 A1 PE20161558 A1 PE 20161558A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- oxy
- refers
- new compound
- sap
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- -1 (2R,2'R)-Bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1'-adipoylbis(pyrrolidine-2-carboxylate) compound Chemical class 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1407506.3A GB201407506D0 (en) | 2014-04-29 | 2014-04-29 | Novel compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161558A1 true PE20161558A1 (es) | 2017-01-06 |
Family
ID=50972033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001934A PE20161558A1 (es) | 2014-04-29 | 2015-04-27 | Nuevo compuesto |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9701668B2 (enExample) |
| EP (1) | EP3137457B1 (enExample) |
| JP (1) | JP6445046B2 (enExample) |
| KR (1) | KR20160145617A (enExample) |
| CN (1) | CN106459016B (enExample) |
| AR (1) | AR100204A1 (enExample) |
| AU (1) | AU2015252184B2 (enExample) |
| BR (1) | BR112016025129A2 (enExample) |
| CA (1) | CA2947060C (enExample) |
| CL (1) | CL2016002721A1 (enExample) |
| CR (1) | CR20160508A (enExample) |
| DO (1) | DOP2016000292A (enExample) |
| EA (1) | EA032129B1 (enExample) |
| ES (1) | ES2731253T3 (enExample) |
| GB (1) | GB201407506D0 (enExample) |
| IL (2) | IL248249A0 (enExample) |
| MA (1) | MA39406B1 (enExample) |
| MX (1) | MX2016014246A (enExample) |
| MY (1) | MY191088A (enExample) |
| PE (1) | PE20161558A1 (enExample) |
| PH (1) | PH12016502006B1 (enExample) |
| SG (1) | SG11201608371RA (enExample) |
| TW (1) | TWI676624B (enExample) |
| UA (1) | UA119871C2 (enExample) |
| UY (1) | UY36098A (enExample) |
| WO (1) | WO2015165833A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| GB201518950D0 (en) * | 2015-10-27 | 2015-12-09 | Glaxosmithkline Ip Dev Ltd | Compound |
| GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2182203T3 (es) | 1997-10-31 | 2003-03-01 | Hoffmann La Roche | Derivados de d-prolina. |
| US6903129B2 (en) * | 2001-12-14 | 2005-06-07 | Hoffman-La Roche Inc. | D-proline prodrugs |
| JP2006526612A (ja) | 2003-06-05 | 2006-11-24 | ファイザー・プロダクツ・インク | ベータ−ラクタマーゼ阻害剤・プロドラッグ |
| GB0313386D0 (en) | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| KR20080004571A (ko) | 2005-04-12 | 2008-01-09 | 메이지 세이카 가부시키가이샤 | 2-티오에테닐 카바페넴 유도체 |
| GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
| UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
-
2014
- 2014-04-29 GB GBGB1407506.3A patent/GB201407506D0/en not_active Ceased
-
2015
- 2015-04-27 EA EA201692185A patent/EA032129B1/ru not_active IP Right Cessation
- 2015-04-27 SG SG11201608371RA patent/SG11201608371RA/en unknown
- 2015-04-27 CN CN201580023347.0A patent/CN106459016B/zh not_active Expired - Fee Related
- 2015-04-27 TW TW104113338A patent/TWI676624B/zh not_active IP Right Cessation
- 2015-04-27 JP JP2016565212A patent/JP6445046B2/ja not_active Expired - Fee Related
- 2015-04-27 UY UY0001036098A patent/UY36098A/es not_active Application Discontinuation
- 2015-04-27 PE PE2016001934A patent/PE20161558A1/es unknown
- 2015-04-27 AU AU2015252184A patent/AU2015252184B2/en not_active Ceased
- 2015-04-27 US US14/787,608 patent/US9701668B2/en not_active Expired - Fee Related
- 2015-04-27 UA UAA201612105A patent/UA119871C2/uk unknown
- 2015-04-27 AR ARP150101262A patent/AR100204A1/es active IP Right Grant
- 2015-04-27 ES ES15720312T patent/ES2731253T3/es active Active
- 2015-04-27 KR KR1020167029703A patent/KR20160145617A/ko not_active Ceased
- 2015-04-27 MY MYPI2016703952A patent/MY191088A/en unknown
- 2015-04-27 CA CA2947060A patent/CA2947060C/en active Active
- 2015-04-27 CR CR20160508A patent/CR20160508A/es unknown
- 2015-04-27 WO PCT/EP2015/058998 patent/WO2015165833A1/en not_active Ceased
- 2015-04-27 MA MA39406A patent/MA39406B1/fr unknown
- 2015-04-27 BR BR112016025129A patent/BR112016025129A2/pt not_active Application Discontinuation
- 2015-04-27 MX MX2016014246A patent/MX2016014246A/es active IP Right Grant
- 2015-04-27 EP EP15720312.6A patent/EP3137457B1/en active Active
-
2016
- 2016-10-09 IL IL248249A patent/IL248249A0/en active IP Right Grant
- 2016-10-10 PH PH12016502006A patent/PH12016502006B1/en unknown
- 2016-10-26 CL CL2016002721A patent/CL2016002721A1/es unknown
- 2016-10-28 DO DO2016000292A patent/DOP2016000292A/es unknown
-
2017
- 2017-06-01 US US15/610,984 patent/US9873686B2/en not_active Expired - Fee Related
- 2017-12-11 US US15/837,297 patent/US10597385B2/en active Active
-
2020
- 2020-12-01 IL IL279120A patent/IL279120A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| MX2013010343A (es) | Composicion y metodos para el transplante de microbiota de colon. | |
| EA202090683A2 (ru) | Способы и композиции для лечения рака | |
| CL2012002896A1 (es) | Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva. | |
| CY1121980T1 (el) | Αντισωματα anti-cd26 και χρησεις εξ αυτων | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| CL2014000458A1 (es) | Compuestos derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina; composicion y combinacion farmaceutica; y uso en el tratamiento o en la prevencion del alzheimer, diabetes tipo 2, obesidad, entre otras enfermedades. | |
| MX375417B (es) | Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado. | |
| ECSP13012609A (es) | Composición farmacéutica | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| CY1120438T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| BR112015027055A8 (pt) | bi-heteroarilas, usos das mesmas, e composição farmacêutica | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| MX380191B (es) | Combinaciones de modalidades para el tratamiento de la diabetes. | |
| PE20171622A1 (es) | Formulacion de relacion fija de insulina glargina/lixisenatida | |
| EA201201623A1 (ru) | Лечение диабета 2 типа | |
| MX2017009294A (es) | Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida. | |
| CO7131387A2 (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| CL2017002326A1 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| MX2014009244A (es) | Una composicion y uso de la misma en el tratamiento de ragades anales. | |
| CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
| EA201691498A1 (ru) | Новая мишень для лечения и профилактики диабета | |
| MX2018013729A (es) | Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma. |